These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34352670)

  • 1. Treatment with fenfluramine in patients with Dravet syndrome has no long-term effects on weight and growth.
    Gil-Nagel A; Sullivan J; Ceulemans B; Wirrell E; Devinsky O; Nabbout R; Knupp KG; Scott Perry M; Polster T; Davis R; Lock M; Cortes RM; Gammaiton AR; Farfel G; Galer BS; Agarwal A
    Epilepsy Behav; 2021 Sep; 122():108212. PubMed ID: 34352670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.
    Bishop KI; Isquith PK; Gioia GA; Gammaitoni AR; Farfel G; Galer BS; Nabbout R; Wirrell EC; Polster T; Sullivan J
    Epilepsy Behav; 2021 Aug; 121(Pt A):108024. PubMed ID: 34023810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients.
    Schoonjans A; Paelinck BP; Marchau F; Gunning B; Gammaitoni A; Galer BS; Lagae L; Ceulemans B
    Eur J Neurol; 2017 Feb; 24(2):309-314. PubMed ID: 27790834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome.
    Schoonjans AS; Ceulemans B
    Expert Rev Neurother; 2022 May; 22(5):351-364. PubMed ID: 33455486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.
    Lagae L; Sullivan J; Knupp K; Laux L; Polster T; Nikanorova M; Devinsky O; Cross JH; Guerrini R; Talwar D; Miller I; Farfel G; Galer BS; Gammaitoni A; Mistry A; Morrison G; Lock M; Agarwal A; Lai WW; Ceulemans B;
    Lancet; 2019 Dec; 394(10216):2243-2254. PubMed ID: 31862249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenfluramine increases survival and reduces markers of neurodegeneration in a mouse model of Dravet syndrome.
    Cha J; Filatov G; Smith SJ; Gammaitoni AR; Lothe A; Reeder T
    Epilepsia Open; 2024 Feb; 9(1):300-313. PubMed ID: 38018342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of fenfluramine in patients with Dravet syndrome: A systematic review and meta-analysis.
    Sharawat IK; Panda PK; Kasinathan A; Panda P; Dawman L; Joshi K
    Seizure; 2021 Feb; 85():119-126. PubMed ID: 33461030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis.
    Zhang L; Li W; Wang C
    Acta Neurol Scand; 2021 Apr; 143(4):339-348. PubMed ID: 33336426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
    Nabbout R; Mistry A; Zuberi S; Villeneuve N; Gil-Nagel A; Sanchez-Carpintero R; Stephani U; Laux L; Wirrell E; Knupp K; Chiron C; Farfel G; Galer BS; Morrison G; Lock M; Agarwal A; Auvin S;
    JAMA Neurol; 2020 Mar; 77(3):300-308. PubMed ID: 31790543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenfluramine HCl (Fintepla
    Sullivan J; Scheffer IE; Lagae L; Nabbout R; Pringsheim M; Talwar D; Polster T; Galer B; Lock M; Agarwal A; Gammaitoni A; Morrison G; Farfel G
    Epilepsia; 2020 Nov; 61(11):2396-2404. PubMed ID: 33078386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison.
    Devi N; Madaan P; Asrar MM; Sahu JK; Bansal D
    Seizure; 2021 Oct; 91():316-324. PubMed ID: 34274891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: A time-to-event analysis.
    Sullivan J; Specchio N; Devinsky O; Auvin S; Perry MS; Strzelczyk A; Gil-Nagel A; Dai D; Galer BS; Gammaitoni AR
    Epilepsia; 2022 Jan; 63(1):130-138. PubMed ID: 34676542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fenfluramine treatment in pediatric patients with Dravet syndrome reduces seizure burden and overall healthcare costs: A retrospective and observational real-world study.
    Gjerulfsen CE; Nikanorova M; Olofsson K; Johannessen Landmark C; Rubboli G; Møller RS
    Epilepsia Open; 2024 Oct; 9(5):1891-1900. PubMed ID: 39140199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.
    Frampton JE
    Drugs; 2023 Jul; 83(10):923-934. PubMed ID: 37316680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany.
    Strzelczyk A; Pringsheim M; Mayer T; Polster T; Klotz KA; Muhle H; Alber M; Trollmann R; Spors H; Kluger G; Kurlemann G; Schubert-Bast S
    Epilepsia; 2021 Oct; 62(10):2518-2527. PubMed ID: 34378197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
    Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A
    Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real-world study.
    Specchio N; Pietrafusa N; Doccini V; Trivisano M; Darra F; Ragona F; Cossu A; Spolverato S; Battaglia D; Quintiliani M; Luigia Gambardella M; Rosati A; Mei D; Granata T; Dalla Bernardina B; Vigevano F; Guerrini R
    Epilepsia; 2020 Nov; 61(11):2405-2414. PubMed ID: 32945537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome: A critical period for early neurodevelopment.
    Bishop KI; Isquith PK; Gioia GA; Knupp KG; Scheffer IE; Nabbout R; Specchio N; Sullivan J; Auvin S; Helen Cross J; Guerrini R; Farfel G; Galer BS; Gammaitoni AR
    Epilepsy Behav; 2023 Jan; 138():108994. PubMed ID: 36463826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long-term open-label safety extension study.
    Lai WW; Galer BS; Wong PC; Farfel G; Pringsheim M; Keane MG; Agarwal A
    Epilepsia; 2020 Nov; 61(11):2386-2395. PubMed ID: 32809271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population.
    Schoonjans AS; Marchau F; Paelinck BP; Lagae L; Gammaitoni A; Pringsheim M; Keane MG; Ceulemans B
    Curr Med Res Opin; 2017 Oct; 33(10):1773-1781. PubMed ID: 28704161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.